This week’s infographic covers some of the largest private equity‑backed dentistry pure‑players in EMEA with approximately €150-€500 million in revenue.
UK for-profit specialist care provider Hesley Group is attempting to chart a new course and move on from its troubled past with plans for 60 new adult care homes to be built by 2030. The Yorkshire-based operator was hit with a major abuse scandal and police investigation in 2022, and then bought by Blandford Capital, a UK private equity firm that helps companies through ‘special situations’, in 2023.
Vivo Capital, a healthcare-focused investment firm, is set to acquire Dutscher Group, a European distributor of laboratory equipment and consumables, from French private equity firm LBO France.
Global pharmaceutical company AstraZeneca is set to make a $15 billion investment in China through 2030 to expand its manufacturing and research and development capabilities in the country.
Nordic occupational health provider Avonova is exploring a potential sale, with private equity firms understood to be in early-stage discussions, according to sources close to the matter.
HBI talks to Jason Powell, CEO of UK Vein Clinic, a low-cost outpatient chain for vericose vein treatment on the company's national expansion and the UK vein care market. UK Vein Clinic has announced plans to expand its network, with the launch of 17 new clinics in 2026.
In November 2025, HBI covered UK Chancellor Rachel Reeves’s call on the Competition and Markets Authority (CMA) to investigate the UK's private dental market. The investigation will examine hidden costs and pricing transparency, the effectiveness of local competition, consumer ability to obtain value for money, and potential overtreatment concerns.
What does this prompt for investigation reveal about the state of UK dental care?
Siegfried, a Switzerland-headquartered pharma Contract Development and Manufacturing Organisation (CDMO), is acquiring three businesses from private equity firm SK Capital: the pharma company Normaco Group, Purisys, a CDMO partner for custom APIs, and Extractas Bioscience, a Tasmania-based botanicals manufacturer.
Private health insurer Bupa and publicly listed not-for-profit insurer HCF are reportedly preparing to lobby the Australian Competition and Consumer Commission (ACCC) to block the acquisition of Canberra-based National Capital Private Hospital (NCPH) by Australia’s largest for-profit hospital group, Ramsay Health Care.
Worldwide Clinical Trials, a US-based contract research organisation (CRO) backed by private equity firm Kohlberg, has agreed to acquire specialised oncology CRO Catalyst Clinical Research from private equity firm QHP Capital.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
